Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Targetable ERBB2 mutations identified in neurofibroma/schwannoma hybrid nerve sheath tumors.

Ronellenfitsch MW, Harter PN, Kirchner M, Heining C, Hutter B, Gieldon L, Schittenhelm J, Schuhmann MU, Tatagiba M, Marquardt G, Wagner M, Endris V, Brandts CH, Mautner VF, Schröck E, Weichert W, Brors B, von Deimling A, Mittelbronn M, Steinbach JP, Reuss DE, Glimm H, Stenzinger A, Fröhling S.

J Clin Invest. 2020 Feb 4. pii: 130787. doi: 10.1172/JCI130787. [Epub ahead of print]

2.

Regorafenib CSF Penetration, Efficacy, and MRI Patterns in Recurrent Malignant Glioma Patients.

Zeiner PS, Kinzig M, Divé I, Maurer GD, Filipski K, Harter PN, Senft C, Bähr O, Hattingen E, Steinbach JP, Sörgel F, Voss M, Steidl E, Ronellenfitsch MW.

J Clin Med. 2019 Nov 21;8(12). pii: E2031. doi: 10.3390/jcm8122031.

3.

Treatment of refractory and superrefractory status epilepticus with topiramate: A cohort study of 106 patients and a review of the literature.

Fechner A, Hubert K, Jahnke K, Knake S, Konczalla J, Menzler K, Ronellenfitsch MW, Rosenow F, Strzelczyk A.

Epilepsia. 2019 Dec;60(12):2448-2458. doi: 10.1111/epi.16382. Epub 2019 Nov 11.

PMID:
31713232
4.

Adrenal Insufficiency in Patients with Corticosteroid-Refractory Cerebral Radiation Necrosis Treated with Bevacizumab.

Voss M, Batarfi A, Steidl E, Wagner M, Forster MT, Steinbach JP, Rödel CM, Bojunga J, Ronellenfitsch MW.

J Clin Med. 2019 Oct 3;8(10). pii: E1608. doi: 10.3390/jcm8101608.

5.

Second Generation mTOR Inhibitors as a Double-Edged Sword in Malignant Glioma Treatment.

Heinzen D, Divé I, Lorenz NI, Luger AL, Steinbach JP, Ronellenfitsch MW.

Int J Mol Sci. 2019 Sep 10;20(18). pii: E4474. doi: 10.3390/ijms20184474.

6.

EGFR and mTOR as therapeutic targets in glioblastoma.

Ronellenfitsch MW, Luger AL, Steinbach JP.

Oncotarget. 2019 Jul 30;10(46):4721-4723. doi: 10.18632/oncotarget.27094. eCollection 2019 Jul 30. No abstract available.

7.

Lack of H3K27 trimethylation is associated with 1p/19q codeletion in diffuse gliomas.

Filipski K, Braun Y, Zinke J, Roller B, Baumgarten P, Wagner M, Senft C, Zeiner PS, Ronellenfitsch MW, Steinbach JP, Plate KH, Gasparoni G, Mittelbronn M, Capper D, Harter PN.

Acta Neuropathol. 2019 Aug;138(2):331-334. doi: 10.1007/s00401-019-02025-9. Epub 2019 May 7. No abstract available.

8.

The physiological mTOR complex 1 inhibitor DDIT4 mediates therapy resistance in glioblastoma.

Foltyn M, Luger AL, Lorenz NI, Sauer B, Mittelbronn M, Harter PN, Steinbach JP, Ronellenfitsch MW.

Br J Cancer. 2019 Mar;120(5):481-487. doi: 10.1038/s41416-018-0368-3. Epub 2019 Feb 12.

9.

Disruption of peroxisome proliferator-activated receptor γ coactivator (PGC)-1α reverts key features of the neoplastic phenotype of glioma cells.

Bruns I, Sauer B, Burger MC, Eriksson J, Hofmann U, Braun Y, Harter PN, Luger AL, Ronellenfitsch MW, Steinbach JP, Rieger J.

J Biol Chem. 2019 Mar 1;294(9):3037-3050. doi: 10.1074/jbc.RA118.006993. Epub 2018 Dec 21.

PMID:
30578297
10.

Akt and mTORC1 signaling as predictive biomarkers for the EGFR antibody nimotuzumab in glioblastoma.

Ronellenfitsch MW, Zeiner PS, Mittelbronn M, Urban H, Pietsch T, Reuter D, Senft C, Steinbach JP, Westphal M, Harter PN.

Acta Neuropathol Commun. 2018 Aug 21;6(1):81. doi: 10.1186/s40478-018-0583-4.

11.

Rescue of 2-Deoxyglucose Side Effects by Ketogenic Diet.

Voss M, Lorenz NI, Luger AL, Steinbach JP, Rieger J, Ronellenfitsch MW.

Int J Mol Sci. 2018 Aug 20;19(8). pii: E2462. doi: 10.3390/ijms19082462.

12.

Doxycycline Impairs Mitochondrial Function and Protects Human Glioma Cells from Hypoxia-Induced Cell Death: Implications of Using Tet-Inducible Systems.

Luger AL, Sauer B, Lorenz NI, Engel AL, Braun Y, Voss M, Harter PN, Steinbach JP, Ronellenfitsch MW.

Int J Mol Sci. 2018 May 17;19(5). pii: E1504. doi: 10.3390/ijms19051504.

13.

CD74 regulates complexity of tumor cell HLA class II peptidome in brain metastasis and is a positive prognostic marker for patient survival.

Zeiner PS, Zinke J, Kowalewski DJ, Bernatz S, Tichy J, Ronellenfitsch MW, Thorsen F, Berger A, Forster MT, Muller A, Steinbach JP, Beschorner R, Wischhusen J, Kvasnicka HM, Plate KH, Stefanović S, Weide B, Mittelbronn M, Harter PN.

Acta Neuropathol Commun. 2018 Mar 1;6(1):18. doi: 10.1186/s40478-018-0521-5.

14.

Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma.

Schäfer N, Proescholdt M, Steinbach JP, Weyerbrock A, Hau P, Grauer O, Goldbrunner R, Friedrich F, Rohde V, Ringel F, Schlegel U, Sabel M, Ronellenfitsch MW, Uhl M, Grau S, Hänel M, Schnell O, Krex D, Vajkoczy P, Tabatabai G, Mack F, Schaub C, Tzaridis T, Nießen M, Kebir S, Leutgeb B, Urbach H, Belka C, Stummer W, Glas M, Herrlinger U.

Neuro Oncol. 2018 Jun 18;20(7):975-985. doi: 10.1093/neuonc/nox204.

15.

Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease.

Burger MC, Ronellenfitsch MW, Lorenz NI, Wagner M, Voss M, Capper D, Tzaridis T, Herrlinger U, Steinbach JP, Stoffels G, Langen KJ, Brandts C, Senft C, Harter PN, Bähr O.

Oncol Rep. 2017 Dec;38(6):3291-3296. doi: 10.3892/or.2017.6013. Epub 2017 Oct 2.

16.

Effects of soluble CPE on glioma cell migration are associated with mTOR activation and enhanced glucose flux.

Ilina EI, Armento A, Sanchez LG, Reichlmeir M, Braun Y, Penski C, Capper D, Sahm F, Jennewein L, Harter PN, Zukunft S, Fleming I, Schulte D, Le Guerroué F, Behrends C, Ronellenfitsch MW, Naumann U, Mittelbronn M.

Oncotarget. 2017 Jun 27;8(40):67567-67591. doi: 10.18632/oncotarget.18747. eCollection 2017 Sep 15.

17.

Mammalian target of rapamycin complex 1 activation sensitizes human glioma cells to hypoxia-induced cell death.

Thiepold AL, Lorenz NI, Foltyn M, Engel AL, Divé I, Urban H, Heller S, Bruns I, Hofmann U, Dröse S, Harter PN, Mittelbronn M, Steinbach JP, Ronellenfitsch MW.

Brain. 2017 Oct 1;140(10):2623-2638. doi: 10.1093/brain/awx196.

PMID:
28969371
18.

Personalized translational epilepsy research - Novel approaches and future perspectives: Part I: Clinical and network analysis approaches.

Rosenow F, van Alphen N, Becker A, Chiocchetti A, Deichmann R, Deller T, Freiman T, Freitag CM, Gehrig J, Hermsen AM, Jedlicka P, Kell C, Klein KM, Knake S, Kullmann DM, Liebner S, Norwood BA, Omigie D, Plate K, Reif A, Reif PS, Reiss Y, Roeper J, Ronellenfitsch MW, Schorge S, Schratt G, Schwarzacher SW, Steinbach JP, Strzelczyk A, Triesch J, Wagner M, Walker MC, von Wegner F, Bauer S.

Epilepsy Behav. 2017 Nov;76:13-18. doi: 10.1016/j.yebeh.2017.06.041. Epub 2017 Sep 13. Review.

PMID:
28917501
19.

Personalized translational epilepsy research - Novel approaches and future perspectives: Part II: Experimental and translational approaches.

Bauer S, van Alphen N, Becker A, Chiocchetti A, Deichmann R, Deller T, Freiman T, Freitag CM, Gehrig J, Hermsen AM, Jedlicka P, Kell C, Klein KM, Knake S, Kullmann DM, Liebner S, Norwood BA, Omigie D, Plate K, Reif A, Reif PS, Reiss Y, Roeper J, Ronellenfitsch MW, Schorge S, Schratt G, Schwarzacher SW, Steinbach JP, Strzelczyk A, Triesch J, Wagner M, Walker MC, von Wegner F, Rosenow F.

Epilepsy Behav. 2017 Nov;76:7-12. doi: 10.1016/j.yebeh.2017.06.040. Epub 2017 Sep 14. Review.

PMID:
28917498
20.

Bevacizumab as a last-line treatment for glioblastoma following failure of radiotherapy, temozolomide and lomustine.

Wenger KJ, Wagner M, You SJ, Franz K, Harter PN, Burger MC, Voss M, Ronellenfitsch MW, Fokas E, Steinbach JP, Bähr O.

Oncol Lett. 2017 Jul;14(1):1141-1146. doi: 10.3892/ol.2017.6251. Epub 2017 May 25.

21.

Myoinositol as a Biomarker in Recurrent Glioblastoma Treated with Bevacizumab: A 1H-Magnetic Resonance Spectroscopy Study.

Steidl E, Pilatus U, Hattingen E, Steinbach JP, Zanella F, Ronellenfitsch MW, Bähr O.

PLoS One. 2016 Dec 29;11(12):e0168113. doi: 10.1371/journal.pone.0168113. eCollection 2016.

22.

CASP9 germline mutation in a family with multiple brain tumors.

Ronellenfitsch MW, Oh JE, Satomi K, Sumi K, Harter PN, Steinbach JP, Felsberg J, Capper D, Voegele C, Durand G, McKay J, Le Calvez-Kelm F, Schittenhelm J, Klink B, Mittelbronn M, Ohgaki H.

Brain Pathol. 2018 Jan;28(1):94-102. doi: 10.1111/bpa.12471. Epub 2017 Apr 17.

PMID:
27935156
23.

Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial.

Herrlinger U, Schäfer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, Friedrich F, Rohde V, Ringel F, Schlegel U, Sabel M, Ronellenfitsch MW, Uhl M, Maciaczyk J, Grau S, Schnell O, Hänel M, Krex D, Vajkoczy P, Gerlach R, Kortmann RD, Mehdorn M, Tüttenberg J, Mayer-Steinacker R, Fietkau R, Brehmer S, Mack F, Stuplich M, Kebir S, Kohnen R, Dunkl E, Leutgeb B, Proescholdt M, Pietsch T, Urbach H, Belka C, Stummer W, Glas M.

J Clin Oncol. 2016 May 10;34(14):1611-9. doi: 10.1200/JCO.2015.63.4691. Epub 2016 Mar 14.

PMID:
26976423
24.

Diagnostic and clinical relevance of the autophago-lysosomal network in human gliomas.

Jennewein L, Ronellenfitsch MW, Antonietti P, Ilina EI, Jung J, Stadel D, Flohr LM, Zinke J, von Renesse J, Drott U, Baumgarten P, Braczynski AK, Penski C, Burger MC, Theurillat JP, Steinbach JP, Plate KH, Dikic I, Fulda S, Brandts C, Kögel D, Behrends C, Harter PN, Mittelbronn M.

Oncotarget. 2016 Apr 12;7(15):20016-32. doi: 10.18632/oncotarget.7910.

25.

Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases.

Harter PN, Bernatz S, Scholz A, Zeiner PS, Zinke J, Kiyose M, Blasel S, Beschorner R, Senft C, Bender B, Ronellenfitsch MW, Wikman H, Glatzel M, Meinhardt M, Juratli TA, Steinbach JP, Plate KH, Wischhusen J, Weide B, Mittelbronn M.

Oncotarget. 2015 Dec 1;6(38):40836-49. doi: 10.18632/oncotarget.5696.

26.

Immunohistochemical Assessment of Phosphorylated mTORC1-Pathway Proteins in Human Brain Tumors.

Harter PN, Jennewein L, Baumgarten P, Ilina E, Burger MC, Thiepold AL, Tichy J, Zörnig M, Senft C, Steinbach JP, Mittelbronn M, Ronellenfitsch MW.

PLoS One. 2015 May 19;10(5):e0127123. doi: 10.1371/journal.pone.0127123. eCollection 2015.

27.

Perioperative cerebral ischemia promote infiltrative recurrence in glioblastoma.

Thiepold AL, Luger S, Wagner M, Filmann N, Ronellenfitsch MW, Harter PN, Braczynski AK, Dützmann S, Hattingen E, Steinbach JP, Senft C, Rieger J, Bähr O.

Oncotarget. 2015 Jun 10;6(16):14537-44.

28.

Sustained focal antitumor activity of bevacizumab in recurrent glioblastoma.

Bähr O, Harter PN, Weise LM, You SJ, Mittelbronn M, Ronellenfitsch MW, Rieger J, Steinbach JP, Hattingen E.

Neurology. 2014 Jul 15;83(3):227-34. doi: 10.1212/WNL.0000000000000594. Epub 2014 Jun 13. Erratum in: Neurology. 2014 Sep 16;83(12):1123.

PMID:
24928118
29.

Hypoxia enhances the antiglioma cytotoxicity of B10, a glycosylated derivative of betulinic acid.

Fischer S, Ronellenfitsch MW, Thiepold AL, Harter PN, Reichert S, Kögel D, Paschke R, Mittelbronn M, Weller M, Steinbach JP, Fulda S, Bähr O.

PLoS One. 2014 Apr 17;9(4):e94921. doi: 10.1371/journal.pone.0094921. eCollection 2014.

30.

PAX2 is an antiapoptotic molecule with deregulated expression in medulloblastoma.

Burger MC, Brucker DP, Baumgarten P, Ronellenfitsch MW, Wanka C, Hasselblatt M, Eccles MR, Klingebiel T, Weller M, Rieger J, Mittelbronn M, Steinbach JP.

Int J Oncol. 2012 Jul;41(1):235-41. doi: 10.3892/ijo.2012.1446. Epub 2012 Apr 25.

31.

Epidermal growth factor receptor and mammalian target of rapamycin as therapeutic targets in malignant glioma: current clinical status and perspectives.

Ronellenfitsch MW, Steinbach JP, Wick W.

Target Oncol. 2010 Sep;5(3):183-91. doi: 10.1007/s11523-010-0154-5. Epub 2010 Sep 19. Review.

PMID:
20853178
32.

The pan-Bcl-2 inhibitor (-)-gossypol triggers autophagic cell death in malignant glioma.

Voss V, Senft C, Lang V, Ronellenfitsch MW, Steinbach JP, Seifert V, Kögel D.

Mol Cancer Res. 2010 Jul;8(7):1002-16. doi: 10.1158/1541-7786.MCR-09-0562. Epub 2010 Jun 29.

33.

Bevacizumab-induced diffusion restriction in patients with glioma: tumor progression or surrogate marker of hypoxia?

Rieger J, Bähr O, Ronellenfitsch MW, Steinbach J, Hattingen E.

J Clin Oncol. 2010 Sep 20;28(27):e477; author reply e478. doi: 10.1200/JCO.2010.29.2029. Epub 2010 Jun 28. No abstract available.

PMID:
20585096
34.

Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death.

Ronellenfitsch MW, Brucker DP, Burger MC, Wolking S, Tritschler F, Rieger J, Wick W, Weller M, Steinbach JP.

Brain. 2009 Jun;132(Pt 6):1509-22. doi: 10.1093/brain/awp093. Epub 2009 May 4.

Supplemental Content

Loading ...
Support Center